Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of DC371739 in Healthy Subjects
NCT04640012Phase 1Completed
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pingvakatin in hyperlipidemia (7 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoints: Number of Participants With Adverse Events, Total urine excretion rate and 1 more. Started Sep 2020; status: completed.
02
Drugs
pingvakatin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT04640012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640012.